Lupin Spins Out Oncology Assets Into Kaveri Therapeutics; Shares Gain Around 1%

Mumbai July, 21: Lupin Ltd. has carved out two of its oncology drug programmes into a newly formed US-based company, Kaveri Therapeutics Inc., in a move aimed at accelerating their clinical development while bringing in external capital.

The transaction was executed through Lupin’s wholly owned subsidiary, Lupin Inc., USA, which granted Kaveri an exclusive, perpetual licence for the oncology candidates LNP7457 (PRMT5) and LNP8701 (SOS1).

Instead of an outright sale, Lupin has chosen a spin-out structure. In return for licensing the two programmes, Lupin Inc. received 332,000 common shares, giving it an 82.2% equity stake in Kaveri. The licensed assets have been valued at US$1.6 million, with the transaction completed on July 20, 2026, according to the company’s exchange filing.

Kaveri, incorporated in Delaware earlier this year, will operate as an independent clinical-stage biotechnology company focused on developing treatments for solid tumours, including lung, pancreatic, ovarian and central nervous system-related cancers.

Lupin said Kaveri will seek fresh funding from outside investors to support global clinical trials, while the new company will also receive seed funding from Lupin as part of the arrangement. The company believes an independent structure will provide greater flexibility to raise capital and speed up development of the two experimental therapies.

Stock Market Snapshot

Investors reacted positively to the strategic restructuring.

Lupin share price was trading at ₹2,502.90, up 0.98%, as of 11:51 AM IST on July 21. The stock edged higher through the session as the market assessed the long-term potential of the company’s oncology strategy.

While the transaction does not have an immediate impact on Lupin’s commercial portfolio, it allows the company to retain majority ownership in the programmes while sharing future development costs with external investors.

Company Background

Lupin is one of India’s largest pharmaceutical companies, with operations spanning branded and generic medicines, complex generics, biotechnology products and active pharmaceutical ingredients. The company has a significant presence across India, the US and several international markets.

Its oncology pipeline includes programmes targeting novel cancer pathways, reflecting Lupin’s broader strategy of expanding its specialty and innovation-led business alongside its established generics franchise.

Conclusion

By moving two early-stage oncology assets into a dedicated biotech platform, Lupin is taking a different route to drug development. The structure allows the company to remain the majority shareholder while creating room for Kaveri Therapeutics to attract specialist funding and focus exclusively on advancing the two cancer programmes. Investors appeared to view the strategy favourably, with the stock trading about 1% higher during Tuesday’s session.

Source:

• https://www.nseindia.com/get-quote/equity/LUPIN/Lupin-Limited
• https://nsearchives.nseindia.com/corporate/Lupin2_21072026072213_Lupin-SE_Intimation_Lupin-Kaveri-21072026.pdf